secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-045886
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial
--------------------------------------------------------------------------------

- Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.
- At 18 months, mean lesion size was 28.2% smaller for zervimesine group compared to placebo.
- Trial concluded early with ~100 of planned 246 enrolled; company focuses resources on Alzheimer's and DLB programs.
- Dry AMD is third indication where zervimesine showed efficacy signals; oral pill vs current injectable treatments.
- Additional safety, demographic, and visual outcome data still being analyzed; results to be presented at medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/0001104659-25-045886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/tm2514313d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer